Elicio Therapeutics, Inc. (ELTX) Stock Forecast
ELTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $13.67 average of analyst targets
- Upside to target
- +776.1% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.42
- 52-week range
- $1.56 – $14.85
ELTX analyst ratings
4 analystsNumber of analysts at each rating.
ELTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ELTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.43 | −$0.48 | −$0.40 | −$0.60 | +28.3% | 4 |
| Current fiscal year (2026) | −$1.89 | −$2.17 | −$1.70 | −$2.58 | +26.8% | 4 |
| Next fiscal year (2027) | −$1.69 | −$2.74 | −$1.10 | −$1.89 | +10.5% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ELTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
ELTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ELTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.50 | −$0.47 | −$0.44 | −$0.44 | −$0.43 | −13.6% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.13 | −$2.07 | −$1.95 | −$1.95 | −$1.89 | −11.5% | 0 up · 0 down |
| Next fiscal year (2027) | −$2.64 | −$2.43 | −$2.17 | −$2.17 | −$1.69 | −35.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ELTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ELTX beat in 3 of 12.
What analysts expect from ELTX
4 analysts cover Elicio Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.67, 776.1% above the latest close of $1.56. Analysts expect earnings of −$1.89 per share for 2026, +26.8% from a year earlier. For 2027 the average estimate is −$1.69 per share. Elicio Therapeutics beat the EPS estimate in 3 of the last 12 quarters.
Related: ELTX income statement, ELTX key metrics, ELTX chart. See the ELTX stock overview for the latest quote and news.
ELTX forecast FAQ
What is Elicio Therapeutics's price target?
The average analyst price target for Elicio Therapeutics is $13.67, 776.1% above the latest close of $1.56.
Is Elicio Therapeutics a buy, hold or sell?
Of 4 analysts covering Elicio Therapeutics, 3 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Elicio Therapeutics's EPS forecast?
Analysts forecast −$1.89 per share for 2026 (range −$2.17 to −$1.70); for 2027 the estimate is −$1.69.
When does Elicio Therapeutics report earnings?
Elicio Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.42.
Does Elicio Therapeutics usually beat earnings estimates?
Elicio Therapeutics reported EPS at or above the analyst estimate in 3 of the last 12 quarters.